Prime MedicinePRME +8.03%25 PB Ratio is 8.07 as of Jun. 28, 2026, which is 150% above its 10-year median of 3.23. GuruFocus rates PRME with a GF Score™ of 25/100. The stock has 5 warning signs investors should review. Among 1,232 Biotechnology companies, Prime Medicine ranks worse than 82.79% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-28), Prime Medicine's share price is $3.43. Prime Medicine's Book Value per Share for the quarter that ended in Mar. 2026 was $0.43. Hence, Prime Medicine's PB Ratio of today is 8.07.
The historical rank and industry rank for Prime Medicine's PB Ratio or its related term are showing as below:
PRME'
s PB Ratio Range Over the Past 10 Years
Min: 1.45 Med: 3.23 Max: 11.3
Current: 8.07
During the past 6 years, Prime Medicine's highest PB Ratio was 11.30. The lowest was 1.45. And the median was 3.23.
PRME's PB Ratio is ranked worse than 82.79% of 1232
companies
in the Biotechnology industry
Industry Median: 2.815
vs PRME: 8.07
During the past 12 months, Prime Medicine's average Book Value Per Share Growth Rate was -47.90% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -41.00% per year.
During the past 6 years, the highest 3-Year average Book Value Per Share Growth Rate of Prime Medicine was 279.60% per year. The lowest was -41.00% per year. And the median was 119.30% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Prime Medicine PB Ratio Related Terms
Prime Medicine PB Ratio Historical Data
* Premium members only.
The historical data trend for Prime Medicine's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Prime Medicine's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Prime Medicine PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Prime Medicine's PB Ratio distribution charts can be found below:
* The bar in red indicates where Prime Medicine's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Prime Medicine's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Prime Medicine (PRME) has a PB Ratio of 8.07 as of Jun. 28, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Prime Medicine and its competitors. This is 150% above median its historical median of 3.23. Over the past decade, Prime Medicine's PB Ratio has ranged from 1.45 to 11.30. According to the industry distribution chart, Prime Medicine ranks #1020 out of 1232 companies in the Biotechnology industry, placing it in the top 82.8%.
Is Prime Medicine's PB Ratio too high?
Prime Medicine's current PB Ratio of 8.07 is 150% above median its 10-year median of 3.23. Over the past 10 years, this metric has ranged from a low of 1.45 to a high of 11.30. The Biotechnology industry median PB Ratio is 2.82. Prime Medicine's value of 8.07 is 186.7% above this industry median. Based on the distribution chart, Prime Medicine ranks #1020 out of 1232 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Prime Medicine has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Prime Medicine's PB Ratio compare to IMMX and SGP?
According to the Biotechnology industry distribution chart, Prime Medicine ranks #1020 out of 1232 companies for PB Ratio. This places Prime Medicine in the lower half of its industry. The industry median PB Ratio is 2.82. Prime Medicine's value of 8.07 is 186.7% above this benchmark. Historically, Prime Medicine's own PB Ratio has ranged from 1.45 to 11.30 over the past decade. While the company's 10-year median is 3.23 vs. the industry median of 2.82, Prime Medicine has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.82, based on 1,232 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Prime Medicine's current PB Ratio of 8.07 is 186.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Prime Medicine and its competitors. For the Biotechnology industry, the median PB Ratio is 2.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Prime Medicine's current PB Ratio is 8.07, which is 150% above median its own 10-year median of 3.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prime Medicine stock overvalued right now?
Prime Medicine (PRME) has a current PB Ratio of 8.07. The current PB Ratio is 8.07, which is 150% above median its 10-year median of 3.23 and 186.7% above the Biotechnology industry median of 2.82. Prime Medicine's overall GF Score™ is 25/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Prime Medicine (PRME), the current PB Ratio is 8.07 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.
25GF Score
Get the complete analysis for PRME
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PRME has been successfully added to your 
